Browsing by Author "Gultekin, M."

Now showing 1 - 2 of 2

Antimicrobial Resistance in Gram-Negative Hospital Isolates: Results of the Turkish Hitit-2 Surveillance Study of 2007
(Taylor & Francis Ltd, 2009) Gur, D.; Hascelik, G.; Aydin, N.; Telli, M.; Gultekin, M.; Ogunc, D.; Yaman, G.
Resistance rates to amikacin, ciprofloxacin, ceftazidime, cefepime, imipenem, cefoperazone/sulbactam and piperacillin/tazobactam in Escherichia coli (n = 438), Klebsiella pneumoniae (n = 444), Pseudomonas aeruginosa (n = 210) and Acinetobacter baumanni (n =200) were determined with E-test in a multicenter surveillance study (HITIT-2) in 2007. ESBL production in Escherichia coli and K. pneumoniae was investigated following the CLSI guidelines. Overall 42.0% of E.coli and 41.4% of K. pneumoniae were ESBL producers. In E. coli, resistance to imipenem was not observed, resistance to ciprofloxacin and amikacin was 58.0% and 5.5% respectively. In K. pneumoniae resistance to imipenem, ciprofloxacin and amikacin was 3.1%, 17.8% 12.4% respectively. In P. aeruginosa the lowest rate of resistance was observed with piperacillin/tazobactam (18.1%). A. baumanni isolates were highly resistant to all the antimicrobial agents, the lowest level of resistance was observed against cefoperazone/sulbactam (52.0%) followed by imipenem (55.5%). This study showed that resistance rates to antimicrobials are high in nosocomial isolates and show variations among the centers.
Comparative Clinical Efficiency of Resveratrol, Allopurinol, and Resveratrol Plus Allopurinol in Canine Visceral Leishmaniasis
(American Veterinary Medical Association, 2025) Erdogan, S.; Erdogan, H.; Ural, K.; Pasa, S.; Gultekin, M.; Balikci, C.; Gunal, I.
Objective To assess the clinical and immunological effectiveness of resveratrol alone or combined with allopurinol for treating canine visceral leishmaniasis (CVL). Methods This study included 50 dogs, 30 diagnosed with CVL and 20 healthy controls. Dogs were classified based on their treatment regime (receiving resveratrol [200 mg/dog/d] and/or allopurinol [10 mg/kg/d]). Clinical scores, anti-leishmanial antibody titers, and routine blood parameters were evaluated on days 0, 15, and 30 after treatment. Results Dogs treated with the combination therapy showed the most substantial improvements, with a 75.77% reduction in clinical scores and an 81.25% reduction in antibody titers. Dogs receiving allopurinol exhibited a 56.25% reduction in clinical scores, while those treated with resveratrol showed a 42.82% reduction. Antibody titers were less significantly reduced in the resveratrol group (67.5%) compared to the allopurinol group (45%). Conclusions Combining resveratrol with allopurinol enhances the therapeutic efficacy for CVL, leading to significant clinical improvements and reductions in antibody titers. Resveratrol alone also demonstrates promising anti-leishmanial effects. Clinical Relevance Resveratrol, either alone or in combination with allopurinol, offers a feasible and effective alternative for improving clinical outcomes in CVL. Its incorporation into standard protocols may enhance treatment strategies in veterinary medicine. ©The authors.